Document Detail

Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.
MedLine Citation:
PMID:  23329540     Owner:  NLM     Status:  MEDLINE    
Rhythm control in atrial fibrillation (AF) can be achieved using pharmacological therapy. Amiodarone is the most efficacious anti-arrhythmic agent; however, its use is limited due to an unfavourable safety profile, including pro-arrhythmia, thyroid, liver, skin and pulmonary complications. Dronedarone, which is structurally similar to amiodarone, was developed to try and achieve a favourable balance of efficacy and risk. Dronedarone has been evaluated in several large clinical trials, which have shown reduced mortality and hospitalization rates in patients with non-permanent AF. In patients with permanent AF and/or heart failure, dronedarone has been shown to cause increased mortality and morbidity and should not be used in these groups. Compared with amiodarone, dronedarone has fewer toxic effects (thyroid, skin, pulmonary) and, although less efficacious, may be used as first-line therapy for maintenance of sinus rhythm in patients with non-permanent AF. Clinicians must be vigilant in monitoring their patients to ensure they do not develop permanent AF or heart failure.
Ahmed M A Adlan; Gregory Y H Lip
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drug safety     Volume:  36     ISSN:  0114-5916     ISO Abbreviation:  Drug Saf     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-02-11     Completed Date:  2013-07-02     Revised Date:  2014-11-17    
Medline Journal Info:
Nlm Unique ID:  9002928     Medline TA:  Drug Saf     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  93-110     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amiodarone / adverse effects,  analogs & derivatives*,  therapeutic use
Anti-Arrhythmia Agents / adverse effects*,  therapeutic use*
Atrial Fibrillation / chemically induced,  drug therapy*
Clinical Trials as Topic
Heart Failure / chemically induced
Heart Rate / drug effects
Risk Assessment
Reg. No./Substance:
0/Anti-Arrhythmia Agents; JQZ1L091Y2/dronedarone; N3RQ532IUT/Amiodarone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A titanium plasma-sprayed cup with and without hydroxyapatite-coating: a randomised radiostereometri...
Next Document:  WHO strategy for collecting safety data in public health programmes: complementing spontaneous repor...